Claims for Patent: 9,962,336

Summary for Patent: 9,962,336

Title:	Extended release suspension compositions
Abstract:	The present invention relates to a method for preparing a stable extended release suspension composition comprising multiple coated cores of an active ingredient by using a suspension base, wherein the suspension base ensures substantially similar in-vitro dissolution release profile of the active ingredient upon storage of the suspension compositions for at least seven days.
Inventor(s):	Singh; Romi Barat (Benares, IN), Kumar; Ashish (Jhajjar, IN), Shear; Rajesh Srikrishan (Gurgaon, IN), Jain; Satish Kumar (Bilaspur, IN), Jain; Paras P. (Amravati, IN)
Assignee:	Sun Pharmaceutical Industries Limited (Mumbai, IN)
Application Number:	15/148,069
Patent Claims:	1. A stable extended release reconstituted powder for suspension composition comprising multiple coated cores of an active ingredient, wherein upon reconstitution with a suspension base, the composition ensures substantially similar in-vitro dissolution release profile of the active ingredient upon storage of the composition upon reconstitution for at least seven days; and wherein the active ingredient is not bound to an ion-exchange matrix; and wherein the suspension base used for reconstitution of the composition is characterized by having the features of: (i) a viscosity in a range of about 500 cps to about 15,000 cps and (ii) an osmolality of at least 1 osmol/kg of the suspension base; wherein the composition upon reconstitution is characterized by having an osmolality ratio of at least about 1, the osmolality ratio being the ratio of the osmolality of the external phase to the osmolality of the internal phase, the external phase being the suspension base without multiple coated cores of the active ingredient and the internal phase being the coated cores of the active ingredient; wherein the osmolality of the internal phase is the osmolality of a solution which prevents significant leaching of the active ingredient from the coated cores into the solution when the coated cores are suspended in said solution; significant leaching being more than 20% of the active ingredient is leached out from the coated cores into the solution: wherein the coated cores consist of a core of an active ingredient and a coating layer over said core comprising one or more release-controlling agents and average diameter of the coated cores ranges from about 150 .mu.m to about 500 .mu.m, and wherein the composition is homogeneous and the active ingredient is layered onto an inert particle to form the core. 2. The stable extended release reconstituted powder for suspension composition of claim 1, wherein the suspension base comprises: (i) a suspending agent; (ii) an osmogent; and (iii) an aqueous vehicle. 3. The stable extended release reconstituted powder for suspension composition of claim 1, wherein the inert particle is selected from the group consisting of a non-pareil seed, a microcrystalline cellulose sphere, a dibasic calcium phosphate bead, a mannitol bead, a silica bead, a tartaric acid pellet, and a wax based pellet. 4. The stable extended release reconstituted powder for suspension composition of claim 2, wherein the osmogent is selected from the group consisting of carbohydrates; water-soluble salts of inorganic acids; water-soluble salts of organic acids; water-soluble amino acids; urea or its derivatives; propylene glycol; glycerin; polyethylene oxide; xanthan gum; hydroxypropylmethyl cellulose; and mixtures thereof. 5. The stable extended release reconstituted powder for suspension composition of claim 2, wherein the suspending agent is selected from group consisting of cellulose derivatives; carbomers; gums; pectin; dextran; gelatin; polyethylene glycols; polyvinyl compounds; sugar alcohols; and mixtures thereof. 6. The stable extended release reconstituted powder for suspension composition of claim 1, wherein the release-controlling agent is selected from the group consisting of a pH-dependent release-controlling agent, a pH-independent release-controlling agent, and mixtures thereof. 7. The stable extended release reconstituted powder for suspension composition of claim 6, wherein the pH-dependent release-controlling agent is selected from the group consisting of acrylic copolymers; cellulose acetate phthalate; cellulose acetate succinates; hydroxyalkyl cellulose phthalates; hydroxyalkyl cellulose acetate succinates; vinyl acetate phthalates; vinyl acetate succinate; cellulose acetate trimelliate; polyvinyl derivatives; zein; shellac; and mixtures thereof. 8. The stable extended release reconstituted powder for suspension composition of claim 6, wherein the pH-independent release-controlling agent is selected from the group consisting of cellulosic polymers; acrylic copolymers; cellulose acetate; polyethylene derivatives; polyvinyl alcohol; polyvinyl acetate; gums; lipids; fatty acids or their salts/derivatives; a mixture of polyvinyl acetate and polyvinyl pyrrolidone; and mixtures thereof. 9. The stable extended release reconstituted powder for suspension composition of claim 1, wherein the active ingredient is selected from the group consisting of metformin, acarbose, miglitol, voglibose, repaglinide, nateglinide, glibenclamide, glimepride, glipizide, gliclazide, chloropropamide, tolbutamide, phenformin, aloglitin, sitagliptin, linagliptin, saxagliptin, rosiglitazone, pioglitazone, troglitazone, faraglitazar, englitazone, darglitazone, isaglitazone, zorglitazone, liraglutide, muraglitazar, peliglitazar, tesaglitazar, canagliflozin, dapagliflozin, remogliflozin, sergliflozin, verapamil, albuterol, salmeterol, acebutolol, sotalol, penicillamine, norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, cefpodoxime, tetracycline, demeclocycline hydrochloride, amoxicillin, clavulanate potassium, azithromycin, losartan, irbesartan, eprosartan, valsartan, diltiazem, isosorbide mononitrate, ranolazine, propafenone, hydroxyurea, hydrocodone, delavirdine, pentosan polysulfate, abacavir, amantadine, acyclovir, ganciclovir, valacyclovir, valganciclovir, saquinavir, indinavir, nelfinavir, lamivudine, didanosine, zidovudine, nabumetone, celecoxib, mefenamic acid, naproxen, propoxyphene, cimetidine, ranitidine, albendazole, mebendazole, thiobendazole, pyrazinamide, praziquantel, chlorpromazine, sumatriptan, bupropion, aminobenzoate, pyridostigmine bromide, potassium chloride, niacin, tocainide, quetiapine, fexofenadine, sertraline, chlorpheniramine, rifampin, methenamine, nefazodone, modafinil, metaxalone, morphine, sevelamer, lithium carbonate, flecainide acetate, simethicone, methyldopa, chlorthiazide, metyrosine, procainamide, entacapone, metoprolol, propanolol hydrochloride, chlorzoxazone, tolmetin, tramadol, bepridil, phenytoin, gabapentin, fluconazole, terbinafine, atorvastatin, doxepine, rifabutin, mesalamine, etidronate, nitrofurantoin, choline magnesium trisalicylate, theophylline, nizatidine, methocarbamol, mycophenolate mofetil, tolcapone, ticlopidine, capecitabine, orlistat, colsevelam, meperidine, hydroxychloroquine, guaifenesin, guanfacine, amiodarone, quinidine, atomoxetine, felbamate, pseudoephedrine, carisoprodol, venlafaxine, etodolac, chondrotin, lansoprazole, pantoprazole, esomeprazole, dexlansoprazole, dexmethylphenidate, methylphenidate, sodium oxybate, valproic acid or its salts, divalproex, topiramate, carbamazepine, oxcarbazepine, and isotretinoin. 10. The stable extended release reconstituted powder for suspension composition of claim 2, wherein the suspension base further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of anti-caking agents, wetting agents, preservatives, buffering agents, flavoring agents, anti-oxidants, chelating agents, solubility enhancing agents, pH modifying agents, adsorbents, complexing agents, and combinations thereof.